Research  >  Research  >  Scientist Profiles  >  Scientists S-Z

Scientist profiles S-Z

SRI profiles

SImron Singh
Simron Singh, MD, MPH, FRCPC

Medical Oncologist
Affiliate scientist

Odette Cancer Centre
Sunnybrook Health Sciences Centre
2075 Bayview Ave., Room T2-107
Toronto, Ontario, Canada
M4N 3M5

Phone: 416-480-4270
Fax: 416-480-6002

Dr. Simron Singh is a medical oncologist and affiliate scientist in the Odette Cancer Research Program at Sunnybrook Research Institute. He is also an assistant professor at the University of Toronto. He completed his B.Sc. and MD at the University of Alberta in Edmonton. He completed postgraduate training in internal medicine at Queen’s University in Kingston and medical oncology at U of T. After completing his clinical training, Dr. Singh completed his master's degree in public health from Harvard University in Boston, U.S.


  • Master of Public Health, 2005, Harvard T.H. Chan School of Public Health, U.S.
  • Doctor of Medicine, 1999, University of Alberta
  • B.Sc., 1995, University of Alberta

Appointments & Affiliations:

Research Foci:

  • Health care services research
  • Resource utilization, health care disparities and wait times
  • Quality improvement and patient physician communication
  • Neuroendocrine. head and neck malignancies

Research Summary:

Dr. Singh's research interests include neuroendocrine carcinomas as well as population health and cancer care utilization discrepancies. He is co-head of a newly established multi-disciplinary specialized neuroendocrine clinic at Sunnybrook’s Odette Cancer Center, one of the first in the region. He is involved in numerous activities in the care of neuroendocrine cancer including the role of ki-67 as a prognostic marker, and the utilization of health care resources in the diagnosis and treatment of neuroendocrine tumour patients.

Selected Publications

See current publication list at PubMed

  1.  Flynn CJ, Khaouam N, Gardner S, Higgins K, Enepekides D, Balogh J, MacKenzie R, Singh S, Davidson J, Poon I. The value of periodic follow-up in the detection of recurrences following radical treatment in locally advanced head and neck cancer. Clin Oncol. 2010 Dec;22(10):868–73. Epub 2010 July 21.
  2. Singh S, Law C. Multidisciplinary reference centres: The care of neuroendocrine tumours. J Oncol Pract. 2010;6(6);e11–e16.
  3. Singh S, Butow P, Charles M, Tattersall MH. Shared decision making in oncology: assessing oncologist behaviour in consultations in which adjuvant therapy is considered after primary surgical treatment. Health Expectations. 2010 Sep;13(3):244–57. Epub 2010 Jun 23. In Press.
  4. Kocha W, Maroun J, Kennecke H, Law C, Metrakos P, Ouellet JF, Reid R, Rowsell C, Shah A, Singh S, Van Uum S, Wong R. Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian national expert group. Current Oncology. 2010 June;17(3);49–64.
  5. Bradbury PA, Zhai R, Hopkins J, Kulke MH, Heist RS, Singh S, Zhou W, Ma C, Xu W, Asomaning K, Ter-Minassian M, Wang Z, Su L, Christiani DC, Liu G. Matrix metalloproteinase 1, 3 and 12 polymorphisms, and esophageal adenocarcinoma risk. Carcinogenesis. 2009 May;30(5):793–8. Epub 2009 Mar 25.
  6. Singh S, Parulear W, Murray N, Feld R, Evans W K, Tu D, Shepherd, FA. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol. 2005 Feb 1:23(4)850–56.

Related News and Stories: